You can access any of the podium or poster presentations’ abstracts by searching for it below. For the 2026 FIP world congress in Montreal, presentations and summaries from invited speakers are available below, while abstracts are published in the Pharmacy Education Journal (PEJ) here.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (0) |
Back to Search
Cost-Effectiveness Analysis of Posaconazole versus Liposomal Amphotericin B in the Treatment of Mucormycosis patients in Iran
- In: Poster Presentation
- At: Stockholm (Sweden) (2017)
- Type: Poster
- Poster code: P-D-022-Monday
- By: TAHERI, Saeed (Shahid Beheshti University of Medical Science, Dept. of pharmacoeconomics and Pharma Management, Tehran, Iran, Islamic Republic Of)
- Co-author(s): Saeed Taheri: Dept. of Pharmacoeconomics and Pharma Management, Shahid Beheshti Univercity of Medical Science, Tehran, Iran, Islamic Republic Of
Leila Zarei: Dept. of Pharmacoeconomics and Pharma Management, Shahid Beheshti Univercity of Medical Science, Tehran, Iran, Islamic Republic Of
Alireza Ghiamat: Dept. of Pharmacoeconomics and Pharma Management, Shahid Beheshti Univercity of Medical Science, Tehran, Iran, Islamic Republic Of
Gholamhossein Mehralian: Dept. of Pharmacoeconomics and Pharma Management, Shahid Beheshti Univercity of Medical Science, Tehran, Iran, Islamic Republic Of - Abstract:
Backgrounds
Mucormycosis is an invasive fungal infection with high mortality specially in decompensated diabetics and immunosuppressed patients. The Mucorales are inherently resistant to most widely used antifungal agents. Liposomal Amphotericin B (AmB) is an appropriate option for empirical therapy, whereas Posaconazole (PCZ), a new.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 23 September 2026